http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 이관순 ( Lee Gwan Sun ) (검색결과 7 건)
- 무료
- 기관 내 무료
- 유료
-
-
-
이관순,김재주,송채석,오춘근,임규상,Lee, Gwan-Sun,Kim, Jae-Ju,Song, Chae-Seok,O, Chun-Geun,Im, Gyu-Sang 대한한방안이비인후피부과학회 2001 한방안이비인후피부과학회지 Vol.14 No.1
Recently many efforts were focused to understand the mechanical insights of melanogenesis to develop the agents for hyper-pigmentation and hypo-pigmentation. In the melanin biosynthetic pathway, tyrosinase is the rate limiting enzyme, and ${\alpha}$-melanocyte stimulating hormone(MSH) or cAMP-elevating agents stimulate melanogenesis and enhance the melanin synthesis and the tyrosinase activity. The author has analyzed the effects of Radix Trichosanthis on the basal melanogenic activities of B16/F10 mouse melanoma cells, and on the ${\alpha}$-MSH or forskolin-induced melanogenesis. Radix Trichosanthis alone markedly suppressed melanin content and tyrosinase activity in a dose-dependent manner. Pretreatment of the cells with Radix Trichosanthis also suppressed the increase of ${\alpha}$-MSH (10 nM) or forskolin (20${\mu}M$)-induced melanin content and tyrosinase activity. The decrease in the tyrosinase activity was paralled by a decrease in the abundance of tyrosinase protein and tyrosinase promoter activity. Pretreatment of the cells with Radix Trichosanthis also inhibited the increase of forskolin($20{\mu}M$) induced the amount of tyrosinase protein and tyrosinase promoter activity. The results of DOPA staining revealed that pretreatment of the cells with Radix Trichosanthis showed less intensity than B16 melanoma cells stimulated with ${\alpha}$- MSH or forskolin. These results suggest that Radix Trichosanthis inhibits melanogenesis and abrogates ${\alpha}-MSH and cAMP-induced melanogenesis in B16 melanoma cells.
-
-
-
게잡이 원숭이에 있어 rHuEPO(HM10760)의 단회 투여 후 혈액학 및 혈액생화학적 변화
김충용(Choong-Yong Kim),이현숙(Hyun-Sook Lee),이필수(Pil-Soo Lee),하창수(Chang-Su Ha),권세창(Se-Chang Kwon),이관순(Gwan Sun Lee),송창우(Chang-Woo Song),한상섭(Sang-Seop Han) 한국독성학회 2006 Toxicological Research Vol.22 No.1
Changes in hematology and serum biochemistry after treatment of recombinant human erythropoietin (rHuEPO, HM10760) were screened in 4 male cynomolgus monkeys (Macaca fascicularis). Four monkeys, composed of a treatment group of HM10760 and a positive control group of Aranesp<SUP>®</SUP>, were subcutaneously administered at same dose of 100 ㎍/㎏. Both groups did not show any change in body weights and food consumption for 4 weeks compared with those of pretreatment. Both groups did not show any change in total leukocyte count (WBC) and platelet count, while both groups showed increased platelet distribution width (PDW) percentage in HM10760 group during a period from day 5 to day 59 and in Aranesp<SUP>®</SUP> group during a period from day 9 to day 26. Both groups showed increases in red blood cells (RBC), hemoglobin (HGB), and hematocrit (HCT) approximately 10 days after treatment compared with those of pretreatment (day 0). The increased levels of RBC, HGB, and HCT were much higher in HM10760 than in Aranesp<SUP>®</SUP> by the increases of 3.2%~ 12.5% for RBC, 3.8%~17.1% for HCT, and 1.85%~11% for HGB. Both groups showed increases in red cells distribution width (RDW) and reticulocyte (RET) compared with those of pretreatment, showing the highest peak from day 9. The increased level of RET lasted up to day 14 in Aranesp<SUP>®</SUP> group, while it lasted up to day 23 in HM10760 group. The increased level of RDW lasted up to day 59, it was much higher in HM10760 by the increase of 10.1%~17.6% than in Aranesp<SUP>®</SUP> group. In serum biochemistry, both groups showed a decrease in chloride level compared with those of pretreatment. These findings indicated that HM10760 increased RBC, HGB, HCT, RDW, and RET compared with those of pretreatment, and the increased levels were much higher in HM10760 than in Aranesp<SUP>®</SUP>.
-
고우석(Woo Suk Koh),김종춘(Jong Choon Kim),차신우(Shin Woo Cha),김영민(Young Min Kim),정성엽(Sung Youb Jung),권세창(Se Chang Kwon),이관순(Gwan Sun Lee) 한국응용약물학회 2002 Biomolecules & Therapeutics(구 응용약물학회지) Vol.10 No.2
HM10411 is a recombinant granulocyte-colony stimulating factor (rG-CSF) that has been developing as a drug for neutropenia. In this study, antigenic potential of HM 10411 was examined by active systemic anaphylaxis (ASA) in guinea pigs and passive cutaneous anaphylaxis (PCA) in guinea pig-guinea pig system. HM10411 was subcutaneously administered at 0, 5, and 50 ㎎/㎏ and also as a suspension with adjuvant (50 ㎎/㎏+FCA). Ovalbumin (OVA) as a suspension with adjuvant was used to induce positive control responses. In the ASA test, no symptoms except urination and evacuation that were considered as physiological phenomena were observed at 0 and 5 ㎎/㎏. Two of 5 animals at 50 ㎎/㎏ showed sneezing, dyspnea, or cyanosis. All animals in the adjuvant mixture group showed severe symptoms of anaphylatic shock and 3 of them died. In the PCA test, no antibody against HM10411 was detected in the sera from the animals sensitized with 0 or 5 ㎎/㎏. Only 1 serum sample from the animals immunized with 50 ㎎/㎏ showed positive reaction against HM10411, while all 5 sera collected from the HM10411 and FCA mixture group contained the HM10411 -specific antibodies. These results suggest HM10411 is considered to have antigenicity in guinea pig.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
